209 related articles for article (PubMed ID: 27216078)
1. Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution.
Bartlett TE; Chindera K; McDermott J; Breeze CE; Cooke WR; Jones A; Reisel D; Karegodar ST; Arora R; Beck S; Menon U; Dubeau L; Widschwendter M
Nat Commun; 2016 May; 7():11620. PubMed ID: 27216078
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers.
Bijron JG; van der Groep P; van Dorst EB; Seeber LM; Sie-Go DM; Verheijen RH; van Diest PJ
Endocr Relat Cancer; 2012 Feb; 19(1):69-81. PubMed ID: 22143498
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Microscopic Changes in Fallopian Tubes of BRCA Mutation Carriers by Morphometric Analysis of Histologic Slides: A Preliminary Pilot Study.
Amit A; Sabo E; Zohar Y; Trugman E; Pranovich I; Reiss A; Matanes E; Klorin G
Int J Gynecol Pathol; 2018 Sep; 37(5):460-467. PubMed ID: 28863070
[TBL] [Abstract][Full Text] [Related]
5. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.
George SH; Milea A; Shaw PA
Clin Cancer Res; 2012 Nov; 18(22):6199-207. PubMed ID: 22967960
[TBL] [Abstract][Full Text] [Related]
6. Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.
Veskimäe K; Staff S; Tabaro F; Nykter M; Isola J; Mäenpää J
Genes Chromosomes Cancer; 2015 May; 54(5):276-87. PubMed ID: 25706666
[TBL] [Abstract][Full Text] [Related]
7. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery.
Rabban JT; Garg K; Crawford B; Chen LM; Zaloudek CJ
Am J Surg Pathol; 2014 Jun; 38(6):729-42. PubMed ID: 24820399
[TBL] [Abstract][Full Text] [Related]
8. Coming into focus: the nonovarian origins of ovarian cancer.
Dubeau L; Drapkin R
Ann Oncol; 2013 Nov; 24 Suppl 8(Suppl 8):viii28-viii35. PubMed ID: 24131966
[TBL] [Abstract][Full Text] [Related]
9. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.
Mingels MJ; Roelofsen T; van der Laak JA; de Hullu JA; van Ham MA; Massuger LF; Bulten J; Bol M
Gynecol Oncol; 2012 Oct; 127(1):88-93. PubMed ID: 22710074
[TBL] [Abstract][Full Text] [Related]
10. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
Kotsopoulos J; Gronwald J; Karlan B; Rosen B; Huzarski T; Moller P; Lynch HT; Singer CF; Senter L; Neuhausen SL; Tung N; Eisen A; Foulkes WD; Ainsworth P; Sun P; Lubinski J; Narod SA;
Gynecol Oncol; 2018 Jul; 150(1):85-91. PubMed ID: 29793803
[TBL] [Abstract][Full Text] [Related]
11. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.
Crum CP; Drapkin R; Kindelberger D; Medeiros F; Miron A; Lee Y
Clin Med Res; 2007 Mar; 5(1):35-44. PubMed ID: 17456833
[TBL] [Abstract][Full Text] [Related]
12. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE
J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912
[TBL] [Abstract][Full Text] [Related]
13. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
Rabban JT; Crawford B; Chen LM; Powell CB; Zaloudek CJ
Am J Surg Pathol; 2009 Jan; 33(1):111-9. PubMed ID: 18830124
[TBL] [Abstract][Full Text] [Related]
14. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
Soslow RA; Han G; Park KJ; Garg K; Olvera N; Spriggs DR; Kauff ND; Levine DA
Mod Pathol; 2012 Apr; 25(4):625-36. PubMed ID: 22193042
[TBL] [Abstract][Full Text] [Related]
15. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.
Carcangiu ML; Peissel B; Pasini B; Spatti G; Radice P; Manoukian S
Am J Surg Pathol; 2006 Oct; 30(10):1222-30. PubMed ID: 17001151
[TBL] [Abstract][Full Text] [Related]
16. A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
McGonigal S; Wu R; Grimley E; Turk EG; Zhai Y; Cho KR; Buckanovich RJ
Gynecol Oncol; 2023 Sep; 176():139-146. PubMed ID: 37535994
[TBL] [Abstract][Full Text] [Related]
17. [Morphologic and immunohistochemical features of Fallopian tubes and ovaries in women with genetic predisposition to ovarian cancer].
Bilyk EA; Buchanskaia LG; Polishchuk LZ; Peëvich T
Vopr Onkol; 2012; 58(4):507-13. PubMed ID: 23607206
[TBL] [Abstract][Full Text] [Related]
18. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
[TBL] [Abstract][Full Text] [Related]
19. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
20. Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond
Samuel D; Diaz-Barbe A; Pinto A; Schlumbrecht M; George S
Cells; 2022 Feb; 11(3):. PubMed ID: 35159349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
